These settings are saved on this browser.
Search by project using a Select2-powered dropdown and view a citizen-friendly summary of project progress, budget absorption, challenges, actions taken, outcomes, and detailed reporting history.
Raw report records returned by the selected filters.
Grouped public projects available in this detailed view.
Reports where implementation challenges were captured.
Reports containing responses, actions, or recommendations.
Summed expenditure across all filtered report entries.
Average performance score from the filtered records.
Share of report records with recorded challenges.
Share of report records with resolutions or recommendations.
Use the Select2 project search, status filter, or keyword search to quickly locate public project reports.
Implementation status mix across the filtered public report records.
Try another project name, status, cluster, challenge, recommendation, or comment.
A simplified view of what is affecting implementation, what is being done, and the latest public-facing outcome.
Issues slowing or affecting delivery
Responses and recommendations captured
Latest reported progress notes
The institution faced breakdown of equipment and a shortfalls of raw materials which limited production capacity.
Replacement of the old equipment with modern and more efficient equipment
The Institution produce 10 million doses of assorted vaccines against a target of 11.25 million doses indicating a 89% achievement over the quarter.
Lack of funding for the projects
The institution seeking authority from Treasury to use own revenue to co-fund the project
Stalled
The Institute encountered breakdown of equipment during the period and shortfall of raw materials which limited production capacity.
Replacement of the old and outdated equipment with modern and efficient equipment
Ongoing
The delay in Modernization of the KEVEVAPI plant has affected the attainment of vaccines production targets as envisaged in MTP IV.
Provide remaining budget of KES 585 Million to finalize the Phase I of the KEVEVAPI Modernization project
The project has experience budgetary issues during the MTP IV period. By 2023/24FY the project expenditure was KES 1,165 Million out of the Project Cost of KES 1,750 Million. The Project requires KES 585 million to finalize the Phase I of Modernization of the plant. The Good Manufacturing Practice Certification (GMP) will increase production of animal vaccine from 45 Million doses to 70 million doses annually and allow access the international markets for the vaccines. However, the production of vaccines is still ongoing at the limited capacity.
The delayed finalization of the Modernization of the KEVEVAPI plant to achieve Good Manufacturing practice limits the production and productivity. Thia is also complicated by reduced demand for vaccines by the Counties.
Finalize the KEVEVAPI Modernization project, harmonize and coordinate the national vaccination
The Production of assorted animal vaccines was 5.5 Million doses against a target of 9.25 Million doses (60%).
Raw report history is kept here for users who need the full records.
| Date | Status | Amount Spent | Performance | Challenges | Recommendations | Comments |
|---|---|---|---|---|---|---|
| 22 Apr 2026 | Ongoing | 0.00 | 89.0% |
The institution faced breakdown of equipment and a shortfalls of raw materials which limited production capacity.
|
Replacement of the old equipment with modern and more efficient equipment
|
The Institution produce 10 million doses of assorted vaccines against a target of 11.25 million doses indicating a 89% achievement over the quarter.
|
| 22 Apr 2026 | Stalled | 0.00 | 69.0% |
Lack of funding for the projects
|
The institution seeking authority from Treasury to use own revenue to co-fund the project
|
N/A
|
| 22 Apr 2026 | Ongoing | 0.00 | 69.0% |
The Institute encountered breakdown of equipment during the period and shortfall of raw materials which limited production capacity.
|
Replacement of the old and outdated equipment with modern and efficient equipment
|
N/A
|
| 11 Feb 2026 | Stalled | 0.00 | 66.0% |
The delay in Modernization of the KEVEVAPI plant has affected the attainment of vaccines production targets as envisaged in MTP IV.
|
Provide remaining budget of KES 585 Million to finalize the Phase I of the KEVEVAPI Modernization project
|
The project has experience budgetary issues during the MTP IV period.
By 2023/24FY the project expenditure was KES 1,165 Million out of the Project Cost of KES 1,750 Million. The Project requires KES 585 million to finalize the Phase I of Modernization of the plant. The Good Manufacturing Practice Certification (GMP) will increase production of animal vaccine from 45 Million doses to 70 million doses annually and allow access the international markets for the vaccines. However, the production of vaccines is still ongoing at the limited capacity.
|
| 11 Feb 2026 | Ongoing | 0.00 | 89.0% |
The delayed finalization of the Modernization of the KEVEVAPI plant to achieve Good Manufacturing practice limits the production and productivity. Thia is also complicated by reduced demand for vaccines by the Counties.
|
Finalize the KEVEVAPI Modernization project, harmonize and coordinate the national vaccination
|
The Production of assorted animal vaccines was 5.5 Million doses against a target of 9.25 Million doses (60%).
|
| 11 Feb 2026 | Ongoing | 0.00 | 23.0% |
The lack of GMP certification limits the expanded production capacity to achieve the MTP IV targets.
|
Finalize the implementation of the Modernization of the KEVEVAPI Plant which requires a budget of KES 585 Million to finalize Phase I of the project.
|
The production of assorted animal vaccines is affected by the delayed Modernization of the Plant to achieve Good Manufacturing (GMP) certification.
During the quarter 8.4 million doses were produced against a target of 9.25 Million (91%).
|
| 11 Feb 2026 | Ongoing | 0.00 | 29.0% |
The production and distribution is mainly driven by the demands from the counties, when the demand is low the production slows down.
|
Harmonize and schedule regular animal vaccinations across the control to facilitate disease control and management.
|
The Production of assorted animal vaccines in Quarter II was 2.3 million doses against a target of 9.25 Million doses (25% of the target). This is affected by low demand by the counties.
|
| 11 Feb 2026 | Ongoing | 0.00 | 20.0% |
The stalling of the modernization component affected the expansion of vaccines production line
|
Fund the KEVEVAPI Modernization project to attain Good Manufacturing Practice (GMP) certification at a cost of KES 585 Million to improve the efficiency and productivity.
|
The increase of vaccines affected by the National Mass Vaccination campaign
|
| 10 Feb 2026 | Ongoing | 0.00 | 50.0% |
Delay finalization of the modernization of plant to a Good Manufacturing Practice (GMP) certification level
|
Allocate funds and expedite the Modernization project
|
Lack of budget provision delayed the project implementation.
The overachievement in vaccines production can be attributed to National Vaccination campaign on FMD and PPR and exports of vaccines.
|
| 09 Feb 2026 | Ongoing | 0.00 | 31.0% |
Poor vaccination programs lacking harmonized vaccination schedules affecting the vaccine production
|
Finalize the Modernization of the plant to achieve Good Manufacturing Practice (GMP) certification to enhance productivity and access the global animal vaccines markets.
Develop and implement a regular nationally coordinated animal vaccination program.
|
The over achievement in the quarter was attributed to the Mass National Campaign initiated by the Government
|